Icosapent Ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.

Icosapent Ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol. Expert Rev Cardiovasc Ther. 2020 Mar 31;: Authors: Bazarbashi N, Miller M Abstract INTRODUCTION: Icosapent Ethyl (IPE) is a highly purified (>96%) form of eicosapentanoic acid, a marine-derived omega-3 fatty acid known to reduce serum triglyceride levels. Experimental and human studies also support anti-atherosclerotic properties of IPE including antioxidant, anti-inflammatory, endothelial and plaque stabilizing effects. In the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT)l),the addition of 4 grams IPE daily resulted in a 25% reduction in cardiovascular events beyond statins and other standard of care therapies. IPE is now the only therapy currently approved by the Food and Drug Administration (FDA) to treat patients with elevated triglycerides (150- 499 mg/dL) with cardiovascular disease (CVD) or Type 2 diabetes mellitus and 2 or more CVD risk factors. This drug profile outlines the risks and benefits attributable to IPE and the patient population for whom treatment has now been proven to be effective in reducing CVD events.Areas Covered: Icosapent Ethyl (IPE) is a highly purified form of eicosapentanoic acid for patients with elevated triglycerides as monotherapy or combined with statins and/or other lipid lowering therapies.The REDUCE-IT Study demonstrated...
Source: Expert Review of Cardiovascular Therapy - Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research